These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 19424060

  • 1. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
    Wierzbicki AS.
    Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
    [Abstract] [Full Text] [Related]

  • 2. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS.
    Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Apr; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 6. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):185-97. PubMed ID: 15653014
    [Abstract] [Full Text] [Related]

  • 10. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Barter PJ, Rye KA.
    Arterioscler Thromb Vasc Biol; 2008 Jan 18; 28(1):39-46. PubMed ID: 17717290
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ, Redfern JS, McGovern ME, Giral P.
    Curr Opin Cardiol; 2011 Sep 18; 26(5):403-11. PubMed ID: 21730827
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.